For people with vitiligo and their caregivers
What this page helps you do
If you have noticed a white or lighter patch and do not yet know what it is, prepare the details that can help a dermatologist assess it—and the questions that can help you leave understanding the diagnosis or the next step toward one.
- Your task
- Organize the information, priorities, and next review needed for a real-world decision.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
What should I bring to the appointment?
Bring a brief chronology of what you noticed, where it appeared, and what changed; a current medicine list; relevant personal and family history; and any prior skin records or treatments. Add the practical and emotional questions you most want answered so they are not lost at the end of the visit. Evidence Evidence Evidence
Why this item matters
Vitiligo assessment relies on history as well as examination. Information about the distribution and change of patches, previous care, associated health history, and the effect on daily life helps the clinician understand both the medical picture and your goals.
How will the clinician decide whether this is vitiligo?
Start by asking what diagnosis the clinician thinks is most likely, what findings support it, and what else was considered. The clinician will usually take a history and examine the affected skin; a dermatologist may also use a Wood’s lamp or examine hair and other areas when relevant. Evidence Evidence Evidence
Why this item matters
NIAMS, AAD, and clinical guidelines place history and skin examination at the center of diagnosis. The clinician is trying to decide whether the change is vitiligo, whether the pattern can be classified, and whether the history suggests recent activity or another explanation.
Should I expect tests?
Tests may be discussed, but they are not a measure of how seriously the clinician takes you. Blood tests, an eye examination, or a skin biopsy may be considered when each would answer a question raised by your history or examination. Evidence Evidence
Why this item matters
NIAMS lists these as possible parts of evaluation, including testing for associated autoimmune disease and biopsy when examining skin tissue would help. Guidelines also consider relevant comorbidity and differential diagnosis in the work-up.
If it is vitiligo, do I need to choose a treatment today?
The conversation should begin with your goals and the clinician’s assessment. Pattern, apparent activity, body sites, age, overall health, prior care, access, and the effect on your life can all shape which options are worth discussing; you do not need to arrive having chosen one. Evidence Evidence Evidence
Why this item matters
Clinical and patient guidance describes several treatment and non-treatment paths and does not identify one universally best choice. A useful discussion distinguishes what an option is intended to do, its burdens and material risks, the evidence behind it, and how progress would be reviewed.
What should I understand before I leave?
Before leaving, try to restate the working diagnosis, the goal of the plan, what you are expected to observe, and how unanswered questions will be revisited. If treatment is discussed, ask the prescribing clinician for the exact instructions and when and how to contact the care team. Evidence Evidence
Why this item matters
Vitiligo guidance treats assessment of activity, response, quality of life, and changing goals as parts of ongoing management. A plan is easier to follow when you understand what is being evaluated rather than receiving only the name of a treatment.
Questions that can change the next decision
- For your clinicianWhat should make me call sooner?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianHow will we decide whether to continue or change the plan?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · independentIndependent source
- Published
- 2022-10-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- American Academy of DermatologyPatient education · not independentIndependence not established
- Published
- 2026-04-15
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.